Shannon Strom, Ph.D., R.A.C.

Prior to joining Satsuma Pharmaceuticals in 2018, Shannon was a member of the global regulatory leadership and drug development teams at Pearl Therapeutics (acquired by AstraZeneca), which developed multiple metered-dose inhaler (MDI) products, including Bevespi Aerosphere and Pearl’s triple combination MDI.  Most recently, she worked in a global regulatory role at Roivant Sciences.  Since beginning her biopharmaceutical industry career in 2005, Shannon has been involved with the development of drugs for various indications in the areas of neurology, psychiatry, pain management, oncology, and respiratory disease. Shannon earned an undergraduate degree in biology from Duke University and a doctorate degree in pharmacology from the University of North Carolina.